Solara Active Pharma Sciences Limited (NSE:SOLARA)
India
· Delayed Price · Currency is INR 476.70
-0.70 (-0.15%)
May 19, 2025, 3:30 PM IST
NSE:SOLARA Income Statement
Financials in millions INR. Fiscal year is April - March.
Millions INR. Fiscal year is Apr - Mar.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2017 - 2020 |
|---|---|---|---|---|---|---|
Period Ending | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 | Mar '21 Mar 31, 2021 | 2017 - 2020 |
| Operating Revenue | 12,838 | 12,889 | 14,438 | 12,683 | 16,169 | Upgrade
|
| Other Revenue | 83.2 | - | - | - | - | Upgrade
|
| Revenue | 12,921 | 12,889 | 14,438 | 12,683 | 16,169 | Upgrade
|
| Revenue Growth (YoY) | 0.24% | -10.73% | 13.84% | -21.56% | 22.33% | Upgrade
|
| Cost of Revenue | 6,264 | 8,629 | 8,389 | 7,079 | 7,705 | Upgrade
|
| Gross Profit | 6,657 | 4,261 | 6,049 | 5,605 | 8,464 | Upgrade
|
| Selling, General & Admin | 2,117 | 2,500 | 2,308 | 2,392 | 2,327 | Upgrade
|
| Other Operating Expenses | 2,394 | 2,703 | 2,353 | 2,349 | 2,205 | Upgrade
|
| Operating Expenses | 5,503 | 6,236 | 5,773 | 5,864 | 5,618 | Upgrade
|
| Operating Income | 1,154 | -1,975 | 275.9 | -259.9 | 2,846 | Upgrade
|
| Interest Expense | -1,148 | -1,001 | -868 | -724.2 | -803.4 | Upgrade
|
| Interest & Investment Income | - | 22.2 | 57.8 | 77.6 | 142.2 | Upgrade
|
| Currency Exchange Gain (Loss) | - | 6.7 | 2.7 | 24.2 | -16.9 | Upgrade
|
| Other Non Operating Income (Expenses) | - | -47.8 | -20.7 | -8.2 | -13.8 | Upgrade
|
| EBT Excluding Unusual Items | 5.4 | -2,995 | -552.3 | -890.5 | 2,154 | Upgrade
|
| Merger & Restructuring Charges | - | - | - | -34.9 | - | Upgrade
|
| Gain (Loss) on Sale of Assets | - | 3.6 | -4.5 | -7.7 | 20 | Upgrade
|
| Other Unusual Items | - | -1,897 | 100.2 | 17.5 | 38.2 | Upgrade
|
| Pretax Income | 5.4 | -4,884 | -448.2 | -911 | 2,215 | Upgrade
|
| Income Tax Expense | - | 785.4 | -225.7 | -328.1 | 1.5 | Upgrade
|
| Earnings From Continuing Operations | 5.4 | -5,670 | -222.5 | -582.9 | 2,214 | Upgrade
|
| Net Income to Company | 5.4 | -5,670 | -222.5 | -582.9 | 2,214 | Upgrade
|
| Minority Interest in Earnings | - | -4.3 | 0.7 | 1.4 | 0.5 | Upgrade
|
| Net Income | 5.4 | -5,674 | -221.8 | -581.5 | 2,214 | Upgrade
|
| Net Income to Common | 5.4 | -5,674 | -221.8 | -581.5 | 2,214 | Upgrade
|
| Net Income Growth | - | - | - | - | 93.18% | Upgrade
|
| Shares Outstanding (Basic) | 39 | 36 | 36 | 36 | 32 | Upgrade
|
| Shares Outstanding (Diluted) | 39 | 36 | 36 | 36 | 34 | Upgrade
|
| Shares Change (YoY) | 7.15% | - | 0.15% | 4.75% | 28.19% | Upgrade
|
| EPS (Basic) | 0.14 | -157.62 | -6.16 | -16.18 | 69.00 | Upgrade
|
| EPS (Diluted) | 0.14 | -157.62 | -6.16 | -16.18 | 64.53 | Upgrade
|
| EPS Growth | - | - | - | - | 50.70% | Upgrade
|
| Free Cash Flow | 1,729 | 678.1 | 449.4 | -4,507 | -190.2 | Upgrade
|
| Free Cash Flow Per Share | 44.82 | 18.84 | 12.48 | -125.38 | -5.54 | Upgrade
|
| Dividend Per Share | - | - | - | - | 7.000 | Upgrade
|
| Dividend Growth | - | - | - | - | 250.00% | Upgrade
|
| Gross Margin | 51.52% | 33.06% | 41.90% | 44.19% | 52.35% | Upgrade
|
| Operating Margin | 8.93% | -15.33% | 1.91% | -2.05% | 17.60% | Upgrade
|
| Profit Margin | 0.04% | -44.02% | -1.54% | -4.58% | 13.69% | Upgrade
|
| Free Cash Flow Margin | 13.38% | 5.26% | 3.11% | -35.53% | -1.18% | Upgrade
|
| EBITDA | 2,146 | -979.8 | 1,315 | 793.3 | 3,872 | Upgrade
|
| EBITDA Margin | 16.61% | -7.60% | 9.11% | 6.25% | 23.95% | Upgrade
|
| D&A For EBITDA | 992.5 | 995.6 | 1,039 | 1,053 | 1,026 | Upgrade
|
| EBIT | 1,154 | -1,975 | 275.9 | -259.9 | 2,846 | Upgrade
|
| EBIT Margin | 8.93% | -15.33% | 1.91% | -2.05% | 17.60% | Upgrade
|
| Effective Tax Rate | - | - | - | - | 0.07% | Upgrade
|
| Revenue as Reported | 12,921 | 12,943 | 14,664 | 12,884 | 16,457 | Upgrade
|
| Advertising Expenses | - | 33 | 8.6 | 3.8 | 3.1 | Upgrade
|
Updated Jan 24, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.